Long-form writing on EVs, grounded in the data.
Articles on extracellular vesicle science, characterization standards, and the questions clinicians and partners actually ask. No press-release cadence. No marketing-grade hedging. The published evidence, read carefully, with the limits stated where they sit.
8 pieces, authored by the founding team.
What extracellular vesicles actually are, and why "exosome" is the wrong word for most products
EVs are not a category of skincare ingredient. They are a class of biological particles defined by how they are made. Three biogenesis routes, three subpopulations, and a vocabulary problem that has shaped the entire commercial market.
Frédéric St-Denis-Bissonnette, PhD
Plant-derived versus mammalian extracellular vesicles, compared honestly
Both are bilayer-enclosed nanoscale particles. The differences in safety, scalability, regulatory pathway, and clinical evidence are not minor. They are the reason the two modalities belong in different parts of the EV product map.
Frédéric St-Denis-Bissonnette, PhD
Cross-kingdom EV signalling: what the evidence supports, and what it does not
Plant-derived EVs are taken up by mammalian cells. Their cargo can modulate gene expression in preclinical models. Clinical translation in human skin is where the evidence base is still maturing. Reading the literature requires holding both at once.
Frédéric St-Denis-Bissonnette, PhD
Extracellular vesicles versus PRP for skin applications
PRP and EV preparations are both growth-factor-rich biological inputs that act through cellular signalling. They differ in origin, consistency, delivery, patient experience, and evidence maturity. Treating them as competitors misses the point.
Frédéric St-Denis-Bissonnette, PhD
The biomolecular corona, and why isolation method changes what an EV product actually is
Two preparations from the same biomass can carry different protein coronas if they were isolated by different methods. The corona is part of the active ingredient. Most commercial EV products do not disclose how it was preserved.
Frédéric St-Denis-Bissonnette, PhD
How to evaluate an EV or exosome product before stocking it
Five criteria: source, particle concentration, Certificate of Analysis, isolation method, cold chain. None are optional. Each one separates a characterized EV preparation from a label that uses the word "exosome" without backing it.
Frédéric St-Denis-Bissonnette, PhD
Aloe barbadensis-derived extracellular vesicles in dermocosmetic formulation
Aloe vera has a 3,000-year cosmetic history. The nanovesicles inside aloe leaf parenchyma are a more recent finding. Their cargo, their stability, and their suitability as a scalable dermocosmetic active deserve separate treatment from the broader plant-EV literature.
Frédéric St-Denis-Bissonnette, PhD
Post-procedure EV protocols: what we can say, and what is still under evaluation
Post-laser, post-microneedling, post-chemical peel: clinics are increasingly asking where EV serums fit. The honest answer requires separating mechanistic plausibility, preclinical signal, and confirmed clinical outcome.
Frédéric St-Denis-Bissonnette, PhD
Working with us on the science.
Clinical evaluators, dermatology partners, and qualified researchers can request the EV SELECT GUIDE or open a direct conversation with the team.